Drug class
Vitamin K antagonist (VKA) oral anticoagulant; indandione derivative
Mechanism of action
Inhibits vitamin K epoxide reductase complex (VKORC1), reducing regeneration of active vitamin K and limiting gamma-carboxylation of coagulation factors II, VII, IX and X and proteins C and S.
General use cases
- Prevention and treatment of thromboembolic disorders, including venous thromboembolism and prevention of stroke in selected patients with atrial fibrillation, in countries where fluindione remains authorised; dose requires INR monitoring and country-specific safety restrictions
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
